Day One Biopharmaceuticals in the spotlight (part II)

Impact of Novartis’ Approval on $DAWN and Confusion Around Endpoint Change

Mar 31, 2023

∙ Paid

Here we continue our boutique coverage of Day One Biopharmaceuticals ($DAWN), following up on our (completely free to readers) deep dive initial post in early March. In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDA approval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the …

Boutique Biotech

Day One Biopharmaceuticals in the spotlight (part II)

Impact of Novartis’ Approval on $DAWN and Confusion Around Endpoint Change

This post is for paid subscribers